Inventor

LANCIA JR DAVID R

US111 patents

⚠️ This page may combine multiple inventors who share the name “LANCIA JR DAVID R”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

LANCIA JR DAVID R

FORMA THERAPEUTICS INC

3-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors

3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors

Compositions for activating pyruvate kinase

Activating pyruvate kinase R

Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors

Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors

Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors

Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors

Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors

Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors

Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

Compositions for activating pyruvate kinase

VALO EARLY DISCOVERY INC

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors

FORMA TM2 INC

Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors

Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

VALO HEALTH INC

3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors